Evidence map›Paper›PMID 32707646›Full record

ArticleCancers2020

CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors.

Sebastian Krug, Julia Weissbach, Annika Blank, Aurel Perren, Johannes Haybaeck, Volker Fendrich, Anja Rinke, Thomas Mathias Gress, Jonas Rosendahl, Patrick Michl

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CUX1 Facilitates the Development of Oncogenic PropertiesFrontiers in molecular biosciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Sebastian KrugDepartment of Internal Medicine I, Martin Luther University, 06120 Halle (Saale), Germany.ORCID 0000-0003-1672-7995
Julia WeissbachDepartment of Internal Medicine I, Martin Luther University, 06120 Halle (Saale), Germany.
Annika BlankInstitute of Pathology, University of Bern, 3008 Bern, Switzerland.
Aurel PerrenInstitute of Pathology, University of Bern, 3008 Bern, Switzerland.
Johannes HaybaeckDepartment of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Volker FendrichDepartment of Endocrine Surgery, Schön Klinik Hamburg Eilbek, 22081 Hamburg, Germany.
Anja RinkeDepartment of Gastroenterology and Endocrinology, Philipps-University, 35043 Marburg, Germany.
Thomas Mathias GressDepartment of Gastroenterology and Endocrinology, Philipps-University, 35043 Marburg, Germany.ORCID 0000-0002-9333-5461
Jonas RosendahlDepartment of Internal Medicine I, Martin Luther University, 06120 Halle (Saale), Germany.ORCID 0000-0003-4513-0506
Patrick MichlDepartment of Internal Medicine I, Martin Luther University, 06120 Halle (Saale), Germany.
Martin Luther University Halle-Wittenberg · DEPhilipps University of Marburg · DEUniversity of Bern · CHInnsbruck Medical University · ATSchön Klinik Hamburg Eilbek · DE

Funding

Deutsche Forschungsgemeinschaft Mi 710/10-1
6 · The paper itself

Abstract

Recently, we identified the homeodomain transcription factor Cut homeobox 1 (CUX1) as mediator of tumour de-differentiation and metastatic behaviour in human insulinoma patients. In insulinomas, CUX1 enhanced tumour progression by stimulating proliferation and angiogenesis in vitro and in vivo. In patients with non-functional pancreatic neuroendocrine tumours (PanNET), however, the impact of CUX1 remains to be elucidated. Here, we analysed CUX1 expression in two large independent cohorts (

Indexed as

apoptosischemotherapyCUX1neuroendocrinepancreasPanNETrecurrence

Identifiers

PMID32707646
PMCPMC7409270
OpenAlexW3042765412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.